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Preservation of health from infectious diseases depends upon both mucosal and
systemic immunity via the collaborative effort of innate and adaptive immune responses.
The proficiency of host immunity stems from robust defense mechanisms—physical
barriers and specialized immune cells—and a failure of these mechanisms leads to
pathology. Intriguingly, immunocompetence to pathogens can be shaped by the gut
microbiome as recent publications highlight a dynamic interplay between the gut
microbiome and host susceptibility to infection. Modulation of host immunity to enteric
pathogens has long been studied where gut bacteria shape multiple facts of both innate
and adaptive immunity. Conversely, the impact of gut commensals on host immunity
to extra-gastrointestinal (GI) tract infections has only recently been recognized. In this
context, the gut microbiome can augment host immunity to extra-GI tract bacterial, viral,
and parasitic pathogens. This review explores the research that affords insight into the
role of the gut microbiome in various infectious diseases, with a particular emphasis on
extra-GI tract infections. A better understanding of the link between the gut microbiome
and infectious disease will be critical for improving global health in the years ahead.
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INTRODUCTION
Infectious diseases plague millions of people every year and are the leading cause of death in low-
income and developing nations (World Health Organization, 2014; see Box 1). Prevention and
treatment of infectious diseases requires a comprehensive understanding of the factors contributing
to transmission and risk of infection. Understanding host biological and immunological factors,
namely the development, function, and distribution of immune cells, associated with pathogens
is important for the development of novel medical interventions and treatments. Yet, we now
know the gut microbiome—the collective group of bacteria, viruses, fungi and their associated
genes abiding within the intestinal tract—must also be considered as playing a significant role in
modulating the host immune response. This microbial community in the gastrointestinal tract
is mainly bacterial, containing four main phyla: Bacteroidetes, Firmicutes, Proteobacteria, and
Actinobacteria (Eckburg et al., 2005). The composition is relatively stable at the phylum level,
but lower taxonomic levels can vary quite widely between two individuals, with differences being
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BOX 1 | WORLDWIDE BURDEN OF INFECTIOUS DISEASE—DOES THE GUT MICROBIOME CONTRIBUTE?
Among the most prevalent infectious diseases are HIV/AIDS, malaria, and tuberculosis (TB) as these contribute to one-third of deaths in developing nations and territories
(Murray et al., 2013). HIV, human immunodeficiency virus, causes significant mortality and morbidity as evidenced by data collected in 2014, which estimated that 1.2
million individuals died due to an HIV infection, or associated illness, and a total of 36.9 million individuals lived with the disease (10 Facts, World Health Organization,
2015). Additionally, nearly 2 million individuals were infected with HIV in 2014, which illustrates the need for improved methods of prevention in communities where HIV
transmission is highest, such as sub-Saharan Africa (HIV/AIDS, World Health Organization, 2015). In addition to HIV, malaria is a leading cause of mortality and morbidity
when compared to other infectious agents. This parasitic disease is caused by Plasmodium spp. and has a global disease burden of 198 million cases and 584,000
deaths across all continents, respectively (World Malaria Report, World Health Organization, 2014). Most of these reported deaths occurred in sub-Saharan Africa in
children under the age of 5 years old (World Malaria Report, World Health Organization, 2014). Another infectious disease that currently afflicts two billion individuals
across the globe is tuberculosis (TB), caused by the bacteriumMycobacterium tuberculosis, with nearly 9 million cases of infection and 1.5 million TB-associated deaths
reported in 2013 (Glaziou et al., 2015).
shaped by factors such as delivery (i.e., vaginal vs. cesarean), diet
and antibiotic use among many others (reviewed by Honda and
Littman, 2012; Chevalier et al., 2015; Mikkelsen et al., 2015).
It has long been speculated that the number of organisms in
the gut is between 1014 and 1015, resulting in approximately
10-times more microbial cells than human cells; however, a
recent calculation determined there are about 1013 bacterial
cells in humans resulting in the microbe to human ratio closer
to 1:1 (Sender et al., 2016). From birth, the gut microbiome
contributes greatly to the development of the neonatal immune
system as germ-free (GF) mice have underdeveloped immune
systems compared to conventionally raised mice (Guarner and
Malagelada, 2003). Even more, the gut microbiome influences
host health throughout the lifespan as it is linked to various
inflammatory and autoimmune conditions, such as irritable
bowel syndrome (Hong and Rhee, 2014), inflammatory bowel
disease (De Cruz et al., 2012), ulcerative colitis (Flanagan et al.,
2011), obesity (Turnbaugh et al., 2006), type 2 diabetes mellitus
(van Olden et al., 2015), metabolic syndrome (Vijay-Kumar et al.,
2010), and multiple sclerosis (Miyake et al., 2015). The gut
microbiome also modulates the immune response to infectious
agents both within and outside of the GI tract. In this review
we first establish the relationship between the gut flora and the
host immune response by discussing several, of the many, intra-
GI tract infections affected by the gut microbiota. From there
we move into a discussion of the role of the gut microbiome in
extra-GI tract infections.
INTERACTIONS BETWEEN THE GUT
MICROBIOME AND GASTROINTESTINAL
TRACT INFECTIONS
Clostridium difficile
Clostridium difficile infection (CDI)1 is a prominent health care-
associated illness that primarily impacts the health of individuals
on long-term antibiotic regimens and individuals receiving
inpatient care at hospitals or nursing homes (Agha, 2012).
Though this gram-positive bacterium is found in the intestinal
tract of humans as part of the normal gut microbiota, it can cause
disease when the gut microbiota community becomes dysbiotic
(Antharam et al., 2013; Koenigsknecht et al., 2015). During
dysbiosis C. difficile is able to interact with the epithelial cell
1Clostridium difficile infection [Online]. Centers for Disease Control and
Prevention. Available online at: http://www.cdc.gov/HAI/organisms/cdiff/
Cdiff_infect.html
lining of the gut and promote a pro-inflammatory response that
causes numerous clinical symptoms associated with a C. difficile
infection, such as diarrhea, abdominal pain and sensitivity,
low-grade fever, anorexia, and bloody stools (Leber et al., 2015).
The composition of the gut bacterial community is predictive
of the degree of C. difficile colonization. More specifically,
Porphyromonadaceae, Lachnospiraceae, Lactobacillus, Alistipes,
and Turicibacter are associated with colonization resistance,
while Escherichia and Streptococcus are associated with increased
susceptibility to C. difficile growth (Schubert et al., 2015).
Consistent with these observations, colonization of GF mice with
Lachnospiraceae resulted in a significant decline in C. difficile
colonization; however GF mice colonized with E. coli did not
provide resistance to C. difficile. These studies demonstrate the
ability of certain bacterial species within the gut to inhibit
or promote CDI, however there remains much to be learned
about the specific gut microbes that promote resistance and
susceptibility to CDI. Beyond the bacterial species that inhibit or
promote CDI it is also important to determine the physiological
mechanisms that explain how differences in the gut community
impact susceptibility to CDI as the metabolic profile of the gut
microbiota certainly influences susceptibility to CDI (Theriot
et al., 2014; Buffie et al., 2015). Antibiotic treatment induces
significant changes in gut bacterial populations, which in turn
influences metabolite levels (Theriot et al., 2014). Following
antibiotic treatment there are changes in the abundance of
primary and secondary bile acids, glucose, free fatty acids,
dipeptides, and sugar alcohols (Theriot et al., 2014). C. difficile
exploits these changes and is capable of using metabolites that
increase in abundance (e.g., mannitol, fucturse, sorbitol, etc.)
as carbon sources for growth. Conversely, certain metabolites
confer resistance to CDI. Bacteria such as Clostridium scindens
that encode the 7α-hydroxysteroid dehydrogenase enzyme,
which is needed for secondary bile acid biosynthesis (e.g.,
deoxycholate and lithocholate) inhibit the growth of C. difficile
(Buffie et al., 2015).
Thoughmuch is still unknown about the relationship between
CDI and the gut microbiome, the use of fecal-derived microbiota
transplantation (FMT) to treat recurrent CDI has shown great
promise in the clinic. For example, FMT has been shown to be
well tolerated with an overall clinical cure rate of 89% (Hirsch
et al., 2015). 68% of these patients responded to one dose of the
orally administered capsules and nearly 21% of patients were
cured of CDI following a second dose. In another study, 79%
of patients with severe and refractory CDI were cured after
intestinal microbiota transplantation (Zainah et al., 2015). These
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studies highlight the success and future potential of FMT for
patients with persistent CDI.
Citrobacter rodentium
Citrobacter rodentium is a gram-negative murine pathogen
that colonizes the intestinal mucosa and is used to model
enteropathogenic and enterohemorrhagic E. coli as well as IBD.
Citrobacter rodentium, along with pathogenic E. coli, depends
on attachment and effacement of intestinal epithelial cells
for colonization. These pathogens bind to intestinal epithelial
cells and disrupt the brush border of the villi while forming
an actin pedestal around the attached bacteria, leading to
epithelial damage and effacement (Wong et al., 2012). Citrobacter
rodentium attachment and colonization cause transmissible
murine crypt hyperplasia, a form of colitis that induces
thickening of the colonic mucosa and inflammation. Ultimately,
this inflammation facilitates a loss of diversity and dysbiosis of
the gut microbiota (Lupp et al., 2007).
As a gastrointestinal pathogen, C. rodentium affects the gut
microbiome composition and is in turn affected by the presence
or absence of the microbiota, promoting colonization resistance
through strategies such as nutrient and niche competition
(Lupp et al., 2007). To determine whether specific members
of the gut microbiome, or the entire community, are required
to prevent C. rodentium infection, GF mice were infected
with C. rodentium followed by colonization with E. coli,
Bacteroides vulgatus, or B. thetaiotaomicron. Colonization with
E. coli, but neither of the Bacteroides species, was effective
at outcompeting C. rodentium (Kamada et al., 2012). This
points to specific commensals as important for resistance to
C. rodentium, and not just the presence or absence of the
gut microbiota as a whole. Additionally, certain gut bacteria
like Lactobacillus plantarum can exert protective effects on
gut integrity by stimulating TLR2 and thus upregulating tight-
junction structures, enhancing epithelial barrier functions and
reducing overall susceptibility to C. rodentium (Karczewski
et al., 2010). Resistance to C. rodentium through the gut
microbiome, as well as resistance to EHEC and EPEC, is
also mediated through the presence of segmented filamentous
bacteria (SFB), which promote Th17 immune responses in the
intestine (Ivanov et al., 2009). During the immune response to
C. rodentium, interleukin-22 (IL-22) is produced by T helper
cells and leads directly to expression of antimicrobial peptides
by Paneth cells that help control C. rodentium; these peptides
include RegIIIβ and RegIIIγ (Zheng et al., 2008), as well as
beta-defensins 1, 3, and 4 (Kamada et al., 2012). Toll-like
receptors (TLRs) and Nod-like receptors (NLRs) contribute to
protection against C. rodentium by sensing various microbe-
associated molecular patterns (MAMPs) such as LPS and
muramyl dipeptide and inducing inflammatory conditions in the
gut (Manigold et al., 2000; Khan et al., 2006; Kanneganti et al.,
2007). If innate immune sensing is impaired, such as in MyD88-
deficient mice, control of C. rodentium by neutrophils is lost
and bacteremia, colitis, and death ensue (Lebeis et al., 2007).
Overall, there is a well-organized response to C. rodentium by
the host, which is mediated by different members of the gut
microbiota.
Toxoplasma gondii
Toxoplasmosis, an infectious disease caused by the parasite
Toxoplasma gondii, prevails around the world and an estimated
60 million individuals within the United States are infected with
this parasite (2013)2 . Transmission of T. gondii occurs through
various routes—congenital transmission, carnivorism, and fecal-
oral transmission—with fecal-oral transmission serving as the
primary source of widespread infection in the United States and
across the globe (2013). Initial control of T. gondii infection
depends on the efficacy of the mucosal immune response,
which includes the collaborative efforts of innate immune
defenses, chemokine and antimicrobial secretions, and antigen
presentation for activation of the adaptive immune response
(Benson et al., 2009). Among these factors, TLR11 is important
for detecting the parasite and the production of protective IL-12
and IFN-γ response (Plattner et al., 2008; Yarovinsky et al., 2008).
In some species, including humans, TLR11 is a pseudogene
(Roach et al., 2005), yet these hosts still produce a protective IL-
12 response by activated dendritic cells (Gazzinelli et al., 1993;
Tosh et al., 2016). Recent work has focused on unveiling the
TLR11-independent mechanism by which human hosts control
T. gondii infection (Benson et al., 2009). Protective immunity is,
at least in part, attributed to gut bacteria that elicit a TLR11-
independent, MyD88-dependent protective immune response
following T. gondii infection. T. gondii infection causes intestinal
damage, which results in commensal bacteria indirectly eliciting
protective immunity. Following intestinal damage commensal
bacteria activate dendritic cells throughMyD88-depentent TLRs,
primarily TLR2, TLR4, and TLR9, resulting in the production of
IL-12 that confers resistance to T. gondii (Benson et al., 2009).
EFFECT OF THE GUT MICROBIOME ON
EXTRA-GASTROINTESTINAL TRACT
INFECTIONS AND VICE VERSA
In addition to the gut microbiota modulating host immunity
to intra-GI tract pathogens, increasing evidence demonstrates
its impact on infectious diseases beyond the GI tract (Table 1).
Conversely, extra-GI tract infections also appear to impact
the composition of the gut microbiota. In the following
section we will discuss current literature specifically focused on
understanding the role of the gut microbiome in modulating the
host immune response to extra-GI tract infections.
Influenza Virus
Flu is an infectious disease in the respiratory tract that
is caused by influenza virus (Monto et al., 2000). Infected
individuals may develop mild symptoms or severe disease that
in some cases leads to death (Monto, 1987). The common
symptoms associated with influenza virus include fever, cough,
pharyngitis, myalgia, and fatigue (Barik, 2012). Additionally,
many patients experience abnormalities in gastrointestinal
function, such as vomiting, diarrhea, and nausea, though these
2Parasites – Toxoplasmosis (Toxoplasma infection) [Online]. Centers for Disease
Control and Prevention. Available online at: http://www.cdc.gov/parasites/
toxoplasmosis/gen_info/faqs.html
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TABLE 1 | Extra-gastrointestinal tract infectious diseases modulated by the gut microbiome.
Beneficial gut microbes Pathogenic gut microbes Effect of gut microbiome Immune Structures/Cells
Influenza virus Lactobacillus (Wang et al., 2014);
gram-positive bacteria (Ichinohe
et al., 2011)
Segmented filamentous bacteria,
Enterobacteriaceae, E. coli
(Wang et al., 2014)
Promote migration of DCs to lung
draining lymph nodes and
subsequent T cell priming
Inflammasomes, pulmonary
DCs, CD8+ T-cells,
influenza-specific antibodies,
CCR9+ CD4+ T-cells, IFN-γ,
IL-15, T-helper cells (e.g., Th17)
LCMV Not determined Not determined Modulate responsiveness to antiviral
immune signals (Abt et al., 2012)
Macrophages LCMV-specific
CD8+ T cells and antibodies
(LCMV-specific IgG)
HIV Lactobacillales, Lactobacillus
(Pérez-Santiago et al., 2013),
Bacteroides uniformis (Mutlu
et al., 2014)
Prevotella-rich communities
(Lozupone et al., 2014)
Patients with more Lactobacillales
showed less intestinal translocation
and better response to ART
(Pérez-Santiago et al., 2013).
Prevotella-rich communities have
been associated with numerous
pro-inflammatory conditions (Scher
et al., 2013)
CD4+ T-helper cells (e.g., Th17),
LPS
Klebsiella
pneumoniae
Proinflammatory microbes
(Fagundes et al., 2012)
IL-10-inducing microbes
(Fagundes et al., 2012)
Commensal bacteria promote
protective pro-inflammatory cytokines
(Fagundes et al., 2012)
IL-10, TLR4, neutrophils
Mycobacterium
tuberculosis
Not determined Lactobacillus (Winglee et al.,
2014), Helicobacter hepaticus
(Arnold et al., 2015),
IL-10-inducing microbes (Arnold
et al., 2015)
Helicobacter hepaticus is associated
with reduced protection against a
Mycobacterium tuberculosis infection
by means of an IL-10-dependent
mechanism (Arnold et al., 2015)
CD4+ T-helper cells (e.g., Th1),
TLRs (TLR1 and TLR2), Th1
cytokines (e.g., IFN-γ, TNF-α,
IL-2, and IL-12), macrophages,
granuloma formation
Plasmodium E. coli O86:B7 (Yilmaz et al.,
2014); Ruminococcus (Mooney
et al., 2015) Lactobacillaceae,
Clostridiaceae (Villarino et al.,
2016)
Rikenellaceae,
Ruminococcaceae,
Bacteroidales, Turicibacter
(Mooney et al., 2015)
Bacteroidaaceae,
Prevotellaceae, Sutterellaceae
(Villarino et al., 2016)
E. coli O86:B7 induces antibodies
cross-reactive with Plasmodium
(Yilmaz et al., 2014); assemblage of
bacteria determine severity of malaria
(Villarino et al., 2016)
Cross-reactive antibodies;
Plasmodium-specific antibodies,
CD4+ T follicular helper cells,
germinal center B cells
symptoms are more common in children than adults (Baden
et al., 2009). The seasonal influenza vaccine moderates the
clinical burden associated with this virus, but the efficacy
of the vaccine depends on the strain of virus dominating
the flu season and the number of people vaccinated. A
more effective approach for preventing and treating infection
warrants an exhaustive understanding of the host-pathogen
interaction.
Protection against an influenza infection is associated with
the diversity and health of the gut microbiome. Recent findings
suggest an important role of gram-positive bacterial populations
within the gut and possibly within the nasal tract in fostering an
adequate immune response to a respiratory influenza infection
(Ichinohe et al., 2011). The gut bacteria provided protection in
part by initiating an appropriate inflammatory response through
activation of inflammasomes. In the absence of inflammasome
activation, lung dendritic cells exhibited reduced migration to
the lung draining lymph node resulting in reduced activation of
CD8+ T cells. These results correlated with impaired expansion
of influenza-specific T cells, influenza-specific antibodies, and
elevated viral titers (Ichinohe et al., 2011).
Mice treated with broad-spectrum antibiotics to diminish
gut bacteria populations followed by infection with influenza
have exacerbated weight loss, a greater drop in blood oxygen
saturation, elevated viral titers in the lung, higher epithelial
cell necrosis, and more cell death in both the bronchiolar
lumen and the bronchiole alveolar lavage (BAL) fluid (Abt
et al., 2012). Even more, GF mice experienced significantly more
weight loss, a weaker ability to clear influenza, diminished virus-
specific antibody titers, and more severe bronchiole epithelial
degeneration when compared to outcomes for conventional
mice (Abt et al., 2012). Consistent with the work by Ichinohe
et al. mice treated with broad-spectrum antibiotics also had
fewer influenza-specific antibodies and influenza-specific T cells.
Together, these findings suggest a modulatory role of the gut
microbiome in eliciting a strong host immune response to
influenza.
Gastrointestinal damage that transpires as a result of a
respiratory influenza infection is a perplexing phenomenon
that is poorly understood. A recent report by Wang et al.
demonstrated pronounced changes in the gut bacterial
assemblage (2014). Populations that are significantly changed
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as a result of an influenza infection included a decrease in
Lactobacillus and increases in both segmented filamentous
bacteria (SFB) and Enterobacteriaceae (Wang et al., 2014).
Influenza-induced gastroenteritis was caused by lung-derived
CD4+ T cell-induced dysbiosis that resulted in the expansion of
Th17 cells and subsequent intestinal injury. Specifically, during
influenza CCR9+ CD4+ T cells are recruited from the lung to
intestinal tissues. CD4+ T cell-produced IFN-γ alters the gut
microbiota composition, including an increase in E. coli that
resulted in the production of IL-15. Increased production of
IL-15 stimulated in situ differentiation of CD4+ T cells into Th17
cells that caused intestinal damage.
LCMV
Lymphocytic choriomeningitis virus (LCMV) is an Arenavirus
that is a naturally occurring rodent pathogen and is often
used to study host-pathogen interactions. There are several
strains of LCMV that differ in their ability to cause acute vs.
chronic infections. Using a strain of LCMV that takes about 1-
month to clear post-infection Abt et al. determined how the
gut microbiome impacted the host immune response following
systemic infection (Abt et al., 2012). Mice treated with antibiotics
to deplete the gut microbiome prior to LCMV infection elicited
an impaired adaptive immune response to LCMV infection.
Specifically, antibiotic treated mice had decreased expansion
of LCMV-specific CD8+ T cells, with an elevated expression
of inhibitory receptors, and decreased titers of LCMV-specific
IgG compared to mice that did not receive antibiotics (Abt
et al., 2012). Consistent with these observations, the impaired
adaptive immune response in antibiotic treated mice correlated
with delayed clearance of LCMV. In addition to changes in
the adaptive immune system, this report demonstrated the
gut microbiota primes macrophages to respond to interferon
stimulation (Abt et al., 2012). Whereas macrophages from
antibiotic treated mice have an impaired ability to respond
to LCMV infection, the viral titers in antibiotic treated and
control mice were similar on day 7 post-infection. Therefore, it
is not clear to what effect gut microbiome-dependent priming
of macrophages contributes to the delayed clearance of LCMV
observed at later time points. One possibility is that the impaired
activity of macrophages contributes to the diminished adaptive
immune response; alternatively the gut microbiotamaymodulate
adaptive immune responses through another mechanism. Taken
together with the previous observations on influenza, the gut
microbiome can affect responses to extra-gastrointestinal tract
viral infections that have no direct interactions with mucosal
surfaces.
HIV
One of the most prevalent infections impacting global health
is human immunodeficiency virus (HIV), which is caused
by a retrovirus that invades and infects immune cells
of its host, specifically helper T cells, macrophages, and
dendritic cells (Kumar et al., 2015). The primary targets
of HIV are helper T cells, CD4+ T cells, which leads to a
progressive loss of these cells over the course of an HIV
infection. Eventually, host CD4+ T cells drop to a level that
cell-mediated immunity of the host ceases, and the likelihood
of opportunistic infections substantially increases (Pollock et al.,
2015).
Recent observations found that individuals with HIV also
have an increased risk for intestinal dysbiosis, culminating in
conditions such as diarrhea, colitis, or even metabolic syndrome
(Lozupone et al., 2013). In the gut, HIV affects the mucosal
immune system by infecting and depleting the Th17 cells in
the gut-associated lymphoid tissue (GALT), beginning during
the acute phase of infection and continuing throughout the
course of the disease (Lozupone et al., 2013). Recent work
explored differences among patients with early HIV infection,
and the findings ultimately suggested that patients with higher
proportions of bacteria from the order Lactobacillales, which
contains Lactobacillus species, showed lower markers of bacterial
translocation, such as LPS in the blood (Pérez-Santiago et al.,
2013). Additionally, higher abundance of Lactobacillales in
patients was positively associated with CD4+ T cell count
and was negatively associated with viral load, indicating that
bacteria from Lactobacillales could in some way modulate
the infectivity or pathology of HIV infection (Pérez-Santiago
et al., 2013). As HIV progresses, translocation of bacteria and
bacterial products can occur; for example, LPS can be more
readily detected in circulation during HIV infection (Brenchley
et al., 2006; Cassol et al., 2010). Translocation during HIV is
also associated with higher levels of immune activation and
inflammation, along with a poorer response to anti-retroviral
therapy (ART) (Brenchley et al., 2006; Cassol et al., 2010).
Overall, there is evidence that HIV can induce inflammation
and gut permeability during the course of infection, but this
pathology can also be partially ameliorated by certain gut
bacteria.
Klebsiella pneumoniae
Klebsiella pneumoniae is a gram-negative human commensal
and is commonly found as part of the oral and gut microbiota.
WhereasK. pneumoniae is a normal oral commensal, nosocomial
infections in the lower respiratory tract can cause significant
diseases, especially in patients that are immunocompromised
and those with inadequate respiratory immunity and function
(Tsay et al., 2002; Jung et al., 2012). It has been observed that
GF mice are more susceptible to pulmonary K. pneumoniae
infection than conventionally raised mice (Fagundes et al.,
2012). Following intratracheal infection with K. pneumoniae
GF mice produced elevated levels of anti-inflammatory IL-
10, reduced neutrophil influx into the lung, and elevated lung
bacterial burden and bacteremia compared to control mice.
Treatment with TLR ligands, specifically TLR4 stimulation,
was sufficient to rescue control of K. pneumoniae infection
in GF mice. These observations clearly identify a role for
commensal flora in shaping the host immune response to
pulmonary K. pneumoniae infection, however these data do
not differentiate the contribution of the lung microbiome
vs. the gut microbiome. Indeed, the lung microbiome is
involved in other disease states, such as disease progression in
cystic fibrosis and asthma (Daniels et al., 2013; Huang et al.,
2014).
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Mycobacterium tuberculosis
Tuberculosis (TB) is an infectious disease caused by
Mycobacterium tuberculosis, an aerobic bacterium that invades
the respiratory tract of human hosts. The bacterium primarily
establishes infection within the lungs of the host, but the infection
can remain latent for the entirety of the host’s lifetime as nearly
one-third of the world’s population has latent TB (Glaziou et al.,
2015). Although, extensive research has been conducted on the
environmental and immunological factors that contribute to TB,
the contribution of the gut microbiome to TB and the effect of
TB on the gut microbiome are relatively unexplored. Winglee
and colleagues conducted a longitudinal study in a mouse model
for TB in order to track changes in the gut microbiome prior to,
during, and subsequent to an aerosol infection ofM. tuberculosis
(2014). Overall, significant changes in the resident microbiome
occurred between infection and death; in particular, there was a
significant loss in gut bacteria diversity initially that was followed
by a recovery in diversity (Winglee et al., 2014). Of note, these
changes in the gut bacteria community occurred very rapidly,
within 6 days after M. tuberculosis infection. Given the ability of
an influenza infection to modulate gut bacteria populations and
intestinal inflammation it would be interesting to know if similar
mechanisms are at play following pulmonary TB infection.
Plasmodium
Malaria is a parasitic infectious disease caused by infection
with Plasmodium species. In 2013, there were at least 198
million infections and 584,000 deaths attributed to Plasmodium
infections, with the majority occurring in sub-Saharan Africa
(World Malaria Report, World Health Organization, 2014). The
life cycle of Plasmodium is complex, involving developmental
stages in the human host as well as in the insect vector, the
Anophelesmosquito. Transmission to the human host is initiated
when infected mosquitoes deposit sporozoites while taking
blood meals; sporozoites enter the bloodstream and migrate
to the liver where they infect hepatocytes (Mota et al., 2001;
Gueirard et al., 2010). Inside the infected hepatocytes sporozoites
differentiate into the asexual merozoites, which are released and
establish cyclical infection of red blood cells (RBCs) causing the
symptomatic blood stage of infection.
Recent publications have identified links between the
gut microbiome and the different developmental stages of
Plasmodium infections in vertebrate hosts. Beginning with the
initial stage of infection, antibodies elicited against glycans
present on gut bacteria are able to cross-react with sporozoites.
Many microbes, including Plasmodium, are able to glycosylate
proteins with the Galα1-3Galβ1-4GlcNAc-R glycan (α-gal)
(Yilmaz et al., 2014). Importantly, humans do not use that
glycosylation pattern and are capable of generating antibody
responses directed against α-gal (Yilmaz et al., 2014). The gut
pathobiont Escherichia coli O86:B7 expresses α-gal that elicits α-
gal-specific antibodies that cross-react with α-gal expressed on
Plasmodium sporozoites (Yilmaz et al., 2014). These antibodies
prevent the ability of sporozoites to emigrate from the skin
and infect hepatocytes. Consistent with this observation, there
was a positive correlation between protection from Plasmodium
falciparum infection and the presence of α-gal-specific IgM,
but not α-gal-specific IgG, in humans (Yilmaz et al., 2014). Of
note, the α-gal-specific antibodies did not have any impact on
Plasmodium infections when sporozoites were injected directly
intravenously or when the pre-erythrocytic stage was bypassed
and mice were directly infected with parasitized RBCs. These
data suggest that certain gastrointestinal bacteria could provide
protection against the early stage of the parasite life cycle
in humans. Similarly, the composition of the stool bacteria
community in Malian children correlated with susceptibility
to P. falciparum infection, however it did not correlate with
progression to febrile malaria (Yooseph et al., 2015). The
consistency of this report with that of Yilmaz et al. (susceptibility
to sporozoite infection but not parasitized RBC infection) raises
the possibility that perhaps Malian children resistant to P.
falciparum infection harbored higher levels of α-gal-specific IgM
titers.
Whereas α-gal-specific antibodies had no effect on the
blood stage infection, it has been shown that differences in
the composition of the gut microbiome in mice modulates
susceptibility to the blood stage infection (Villarino et al.,
2016). In this study, C57BL/6 mice from different commercial
vendors (Jackson Labs (Jax), Taconic Biosciences (Tac), National
Cancer Institute/Charles River Labs (NCI), and Harlan/Envigo
(Har)) were infected with P. yoelii 17XNL, a rodent-specific
Plasmodium species. Following infection the severity of malaria
was substantially more pronounced in NCI and Har mice
compared to Jax and Tac mice. 16S rRNA sequencing from GI
samples showed that P. yoelii-resistant Jax and Tac mice were
enriched for Lactobacillaceae and Clostridiaceae, while P. yoelii-
susceptible NCI and Har mice were enriched for Bacteroidaceae,
Prevotellaceae, and Sutterellaceae. Moreover, colonization of
GF mice with cecal content from severe malaria-resistant
Jax or-susceptible NCI mice transferred the susceptibility
phenotypes, respectively. The report also demonstrated that the
gut microbiome could be modulated to decrease susceptibility
to severe malaria (Villarino et al., 2016). Examination of the
immune response following P. yoelii infection showed an increase
in the number of germinal center B cells and accelerated
antibody class switching in Jax mice compared to NCI mice,
which correlated with decreased parasite burden in the Jax
mice (Villarino et al., 2016). Taken together, these publications
show that the gut microbiome affects Plasmodium infections at
different points in its life cycle through distinct mechanisms.
Recent reports also demonstrated that the dialog between
the gut microbiota and Plasmodium is bi-directional. Following
infection of mice with P. yoelii there is an initial decrease
in the alpha diversity and overall abundance of fecal bacteria
that returns to pre-infection levels following resolution of the
infection (Mooney et al., 2015). The mechanism responsible
for this change in gut bacterial composition following P.
yoelii infection is not known, however it does correlate with
sequestration of infected red blood cells in the intestinal
vasculature and infiltration of inflammatory immune cells.
Similarly, in C57BL/6 mice infected with Plasmodium berghei
ANKA, which causes experimental cerebral malaria, it has been
observed that dysbiosis of the gut microbiota, sequestration
of red blood cells in the intestinal vasculature, and intestinal
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lesions occur during infection, however these differences were
not observed in BALB/c mice that are resistant to experimental
cerebral malaria (Taniguchi et al., 2015). It remains unclear
whether dysbiosis of the gut microbiota observed following
Plasmodium infection is an effect of the infection, or if the
dysbiosis contributes to the severity of malaria. Of note,
changes in bacterial diversity have important implications for
the role of Plasmodium in the pathogenicity of Salmonella
enterica serotype Typhimurium. Plasmodium infections, in both
mice and humans, increase susceptibility to invasive bacterial
infections, in particular non-typhoid Salmonella (Scott et al.,
2011; Cunnington et al., 2012; Chau et al., 2013; Mooney et al.,
2014). Mooney et al. colonized GF mice with cecal contents from
either P. yoelii-infected or uninfected control mice followed by
Salmonella infection; mice that received cecal content from P.
yoelii infected mice had a higher burden of Salmonella in feces
than control mice (Mooney et al., 2015). Therefore, not only does
Plasmodium infection induce dysbiosis of the gut microbiota, but
this dysbiosis also leaves the host susceptible to enteric pathogen
infections. However, a mechanism for how this occurs has not
been elucidated.
CONCLUSION
While this review has highlighted recent insight into gut
microbiome-dependent control of extra-GI tract infections, there
is still much that is unknown. One of the biggest obstacles
facing the field is the lack of specific mechanisms that have
been elucidated. With the identification of each mechanism,
the potential for future therapeutics increases drastically. For
example, it has been observed that in mice, short chain fatty acids
(SCFAs) such as propionate can circulate to the bone marrow
and induce generation of antigen-presenting cells (APCs) that
induce diminished Th2 response and thus ablates allergic airway
disease (Trompette et al., 2014). An excellent source of SCFAs is
fermentation of dietary fiber by the gut microbiome, particularly
members of Bacteroidetes and Bifidobacteria (Trompette et al.,
2014). Thus, uncovering mechanistic interactions between the
gut microbiome and the host in the context of extra-GI tract
infections should be a top priority.
Although, decades of research have linked the gut flora with
susceptibility to enteric pathogens, research in recent years
has now demonstrated that the gut microbiota also impact
the host immune response to extra-GI tract infections. This
effect may not be universal, yet we should not be surprised to
learn of other systemic infections that are modulated by gut
commensals. It is also becoming increasingly clear that systemic
infections can also alter the composition of the gut microbiota.
Collectively, these observations point toward novel therapeutic
interventions for pathogens, such as Plasmodium, that have
evaded the development of effective vaccines. Therefore, it
is essential we gain a greater understanding of how the gut
microbiota communicates with the immune system to affect the
outcome of systemic infections.
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